3 ms·
From the paper: At moderate doses, celecoxib was found to be noninferior to ibuprofen or naproxen with regard to cardiovascular safety. (Funded by Pfizer; Clin
by chmaynard 10y ago
From the paper:
At moderate doses, celecoxib was found to be noninferior to ibuprofen or naproxen with regard to cardiovascular safety. (Funded by Pfizer; ClinicalTrials.gov number, NCT00346216.)
http://www.nejm.org/doi/full/10.1056/NEJMoa1611593 http://www.nejm.org/doi/full/10.1056/NEJMoa1611593
The paper draws no conclusions about the relative safety of ibuprofen. The only claim is that celecoxib is not inferior to the other two NSAIDs.
Note that this research study was funded by Pfizer, the company that markets Celebrex.
- gcp 10y agoRight, so this mentions ibuprofen explicitly, and it talks about cyclooxygenase-2 selective inhibitors too. I still don't get what your complaint about TIME's title is? Did you think they should've mentioned celecoxib? That's much less known drug. Mentioning ibuprofen means it's more likely to reach the audience that should care about the study.
- chmaynard 10y agoYes, but we don't know whether Pfizer is hiding other similar studies that came to different conclusions. This is a general problem with big pharma research disclosure, not just Pfizer. FYI, celecoxib is the generic name for Celebrex.